IL216414A - Polynucleotide encoded into a polypeptide of neurotoxin, a vector and a host cell containing it and its uses for drug preparation - Google Patents

Polynucleotide encoded into a polypeptide of neurotoxin, a vector and a host cell containing it and its uses for drug preparation

Info

Publication number
IL216414A
IL216414A IL216414A IL21641411A IL216414A IL 216414 A IL216414 A IL 216414A IL 216414 A IL216414 A IL 216414A IL 21641411 A IL21641411 A IL 21641411A IL 216414 A IL216414 A IL 216414A
Authority
IL
Israel
Prior art keywords
medicament
vector
preparation
host cell
polynucleotide encoding
Prior art date
Application number
IL216414A
Other languages
English (en)
Hebrew (he)
Other versions
IL216414A0 (en
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IL216414A0 publication Critical patent/IL216414A0/en
Publication of IL216414A publication Critical patent/IL216414A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
IL216414A 2009-07-02 2011-11-17 Polynucleotide encoded into a polypeptide of neurotoxin, a vector and a host cell containing it and its uses for drug preparation IL216414A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27019809P 2009-07-02 2009-07-02
EP09164365 2009-07-02
PCT/EP2010/059398 WO2011000929A1 (en) 2009-07-02 2010-07-01 Neurotoxins exhibiting shortened biological activity

Publications (2)

Publication Number Publication Date
IL216414A0 IL216414A0 (en) 2012-02-29
IL216414A true IL216414A (en) 2016-08-31

Family

ID=40911088

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216414A IL216414A (en) 2009-07-02 2011-11-17 Polynucleotide encoded into a polypeptide of neurotoxin, a vector and a host cell containing it and its uses for drug preparation

Country Status (14)

Country Link
US (4) US8586329B2 (enExample)
EP (1) EP2449101B1 (enExample)
JP (2) JP6059986B2 (enExample)
KR (2) KR101818895B1 (enExample)
CN (1) CN102471765B9 (enExample)
AU (1) AU2010267963B2 (enExample)
BR (1) BRPI1014253A2 (enExample)
CA (1) CA2763692A1 (enExample)
ES (1) ES2693705T3 (enExample)
IL (1) IL216414A (enExample)
IN (1) IN2012DN00733A (enExample)
MX (2) MX352265B (enExample)
RU (1) RU2582266C2 (enExample)
WO (1) WO2011000929A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9746475B2 (en) 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
JP6162135B2 (ja) * 2011-11-09 2017-07-12 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 短縮された生物活性を示す神経毒
WO2014029497A1 (en) 2012-08-20 2014-02-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of recombinant proteins harbouring an n-terminal lysine
GEP201706623B (en) 2012-10-16 2017-02-10 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
WO2015188942A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154635A1 (en) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US20170119863A1 (en) * 2014-06-13 2017-05-04 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US20170189500A1 (en) 2014-06-13 2017-07-06 Merz Pharma Gmbh & Co. Kgaa Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders
MX380066B (es) 2014-12-23 2025-03-11 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulinica.
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
CA2979120A1 (en) * 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
US20180128830A1 (en) * 2015-04-16 2018-05-10 Juliet V. Spencer Detection of human cytomegalovirus in breast cancer
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
KR101793328B1 (ko) * 2015-07-03 2017-11-03 씨제이제일제당 (주) Ｌ-라이신 생산능을 갖는 미생물 및 이를 이용한 ｌ-라이신 생산 방법
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
MX395130B (es) 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica
KR102534027B1 (ko) * 2016-06-02 2023-05-18 호유 가부시키가이샤 알 알레르기의 항원
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
MY191843A (en) * 2016-11-28 2022-07-18 C Lecta Gmbh Trehalose phosphorylase
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
JP7365707B2 (ja) * 2018-03-12 2023-10-20 コナゲン インコーポレイテッド ステビオール配糖体レバウジオシドｊ及びレバウジオシドｎの生合成による製造
MA51996A (fr) * 2018-03-13 2021-01-20 Smivet B V Anticorps à domaine unique se liant à la neurotoxine tétanique
US10751399B2 (en) * 2018-03-20 2020-08-25 Cho Pharma Usa, Inc. Chimeric antigen receptors that bind to SSEA4 and uses thereof
JP7311496B2 (ja) * 2018-05-02 2023-07-19 天野エンザイム株式会社 改変型エステラーゼ及びその用途
CN108588087B (zh) * 2018-05-16 2022-06-03 南京农业大学 一种提高植物抗病性的基因GmLecRK-R及其应用
CN111757931B (zh) * 2018-12-21 2023-11-28 福尼亚生物处理股份有限公司 变体g6p g7p葡糖淀粉酶组合物及方法
CN109998055B (zh) * 2019-04-09 2022-03-25 黑龙江省科学院大庆分院 一种汉麻籽抗氧化多肽咀嚼片及其制备方法
CN110100945B (zh) * 2019-05-05 2022-05-03 黑龙江省科学院大庆分院 一种汉麻降血脂肽组合物及其应用
CN114391046A (zh) * 2019-06-21 2022-04-22 苏州晶睿生物科技有限公司 一种检测非洲猪瘟病毒的方法和试剂盒
CN110295150A (zh) * 2019-07-17 2019-10-01 天津润德生物科技有限公司 一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
CN110540996B (zh) * 2019-08-29 2022-01-28 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
CN110643616A (zh) * 2019-10-22 2020-01-03 云南省烟草农业科学研究院 一种烟草降烟碱合成调控基因NtERF91的克隆和应用
IL295797A (en) * 2020-02-22 2022-10-01 Japan Chem Res Human transfer receptor binding peptide
CN112540178B (zh) * 2020-08-06 2023-12-19 武汉天德生物科技有限公司 一种检测早期老年痴呆症的免疫组化试剂盒及其使用方法
CN116615254A (zh) * 2020-10-16 2023-08-18 韩美药品株式会社 对胰高血糖素、glp-1和gip受体全部具有活性的三角激动剂在治疗呼吸道感染性疾病后的后遗症中的用途
CN112662644B (zh) * 2021-01-19 2022-04-22 华南理工大学 一种甘油磷酸二酯磷酸二酯酶突变体及其应用
CN113899907B (zh) * 2021-09-07 2023-06-27 中国农业科学院油料作物研究所 一步式高效筛选黄曲霉毒素绿色防控材料的方法及其应用
CN117192109A (zh) * 2022-05-30 2023-12-08 兰州大学 一种新型冠状病毒抗体检测试纸条
CN115109759B (zh) * 2022-06-24 2024-05-03 浙江工业大学 羰基还原酶LsCR突变体、工程菌及在不对称还原羰基化合物制备手性醇中的应用
CN115944721B (zh) * 2022-12-14 2025-11-25 内蒙古华希生物科技有限公司 一种免疫组合物、其制备方法及应用
CN117741160B (zh) * 2023-12-21 2024-07-12 汉王科技股份有限公司 嗅觉受体在识别乙醇中的用途和检测乙醇的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20060004334A1 (en) 2004-06-30 2006-01-05 Kimberly-Clark Worldwide, Inc. Stabilized absorbent structures
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
EP1786459B1 (en) 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin

Also Published As

Publication number Publication date
RU2582266C2 (ru) 2016-04-20
US20160030511A1 (en) 2016-02-04
US9827298B2 (en) 2017-11-28
CN102471765B9 (zh) 2016-07-27
KR20170016529A (ko) 2017-02-13
AU2010267963A1 (en) 2011-12-22
BRPI1014253A2 (pt) 2016-04-12
CN102471765A (zh) 2012-05-23
KR101818895B1 (ko) 2018-01-15
MX2011013014A (es) 2012-01-27
US20140045760A1 (en) 2014-02-13
MX352265B (es) 2017-11-16
HK1171246A1 (zh) 2013-03-22
EP2449101B1 (en) 2018-10-10
US9193771B2 (en) 2015-11-24
US20120107362A1 (en) 2012-05-03
JP2015231378A (ja) 2015-12-24
IN2012DN00733A (enExample) 2015-06-19
RU2012103376A (ru) 2013-08-10
IL216414A0 (en) 2012-02-29
ES2693705T3 (es) 2018-12-13
JP2012531191A (ja) 2012-12-10
WO2011000929A1 (en) 2011-01-06
CN102471765B (zh) 2016-05-11
US8586329B2 (en) 2013-11-19
US9511114B2 (en) 2016-12-06
JP6059986B2 (ja) 2017-01-11
CA2763692A1 (en) 2011-01-06
EP2449101A1 (en) 2012-05-09
US20170072030A1 (en) 2017-03-16
KR20120104140A (ko) 2012-09-20
AU2010267963B2 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
IL274798B (en) Ph20 polypeptide variants, formulations and uses thereof
IL262667B (en) An isolated polynucleotide encoding a polypeptide and a pharmaceutical composition comprising the isolated polynucleotide
ZA201300147B (en) Recombinant host cells comprising phosphoketolases
AU2016202426A1 (en) Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
IL222027A (en) Peptides and their use
SG10201510704PA (en) Modified factor ix polypeptides and uses thereof
PL2588491T3 (pl) Nowy peptyd i jego zastosowanie
SG10201601327RA (en) Glycosylated polypeptide and drug composition containing said polypeptide
SG173751A1 (en) Foxm1 peptides and vaccines containing the same
IL222966A0 (en) Neuregulin isoforms, neuregulin polypeptides and uses thereof
EP2593595A4 (en) NOVEL PEPTIDES AND USES THEREOF
PL2248533T3 (pl) Polipeptyd pochodzący od enterokoka i jego zastosowanie do szczepienia
ZA201303886B (en) Tomm34 peptides and vaccines including the same
IL214453A0 (en) Vangli peptides and vaccines including the same
IL221474A0 (en) Hjurp peptides and vaccines including the same
IL219927A0 (en) Mybl2 peptides and vaccines containing the same
ZA201200046B (en) Therapeutic peptides, polypeptides and nucleic acid sequences
IL215268A0 (en) C6orf167 peptides and vaccines containing the same
SG11201400289SA (en) Glycosylated polypeptide and drug composition containing said polypeptide
ZA201207342B (en) Ect2 peptides and vaccines including the same
SG10201602076QA (en) Glycosylated polypeptide and pharmaceutical composition containing same
IL220146A0 (en) Tmem22 peptides and vaccines including the same
IL225553A0 (en) 54orf18c peptides and vaccines containing them
PL391975A1 (pl) Białko rekombinowane, kodujący je polinukleotyd oraz sposób otrzymywania insuliny lub jej analogu
GB0921328D0 (en) Therapeutic peptides, polypeptides and nucleic acid sequences

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees